Ella
(Ulipristal)ApprovedSmall molecule
Ella is one of 71 small molecule programs targeting Uterine Fibroid. It is currently in Approved.
2
Indications
5
Total Trials
0
Active Trials
70
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Revia
TevaPhase 3
Leuprorelin
TakedaPhase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Ella
LLaboratoire français de Fractionnement et de Biotechnologies
Approved
Estradiol/norethindrone Acetate
AbbViePhase 3
EE20/DRSP(BAY86-5300)
BayerPhase 3
Indole-3-Carbinol
UUniversity of Kansas Medical Center
Phase 3
Cannabidiol Extract
MMilton S. Hershey Medical Center
Phase 3
Merional
CCairo University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Uterine Fibroid2 trials
Treatment1 trial
UA Versus UAE in Treatment of Fibroids
Completed·—·Phase 4·NCT04832906·70 enrolled
Regulatory
FDA Approval Timeline[4]
Aug 13, 2010
ELLA
NDA NDA022474
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ulipristal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Ella. U.S. Food & Drug Administration.
- [6]